Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Table 3 Best overall response ^a by RRM1 , RRM2B , and 2R status

Response	RRM1 ^b				RRM2B ^c				2R^d
	Normal		Aberrant		Normal		Aberrant		Normal		Aberrant
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
CR	3	(2.3)	2	(7.1)	3	(2.2)	2	(9.1)	2	(1.8)	3	(6.7)
PR	39	(29.8)	12	(42.9)	45	(32.8)	6	(27.3)	36	(31.6)	15	(33.3)
Total responses	42	(32.0)	14	(50.0)	48	(35.0)	8	(36.4)	38	(33.3)	18	(40.0)
95% CI		(24.2 to 40.8)		(30.7 to 69.4)		(27.1 to 43.7)		(17.2 to 59.3)		(24.8 to 42.8)		(25.7 to 55.7)
SD	63	(48.1)	10	(35.7)	63	(46.0)	10	(45.4)	54	(47.4)	19	(42.2)
PD	18	(13.7)	1	(3.6)	15	(11.0)	4	(18.2)	14	(12.3)	5	(11.1)
Unknown	8	(6.1)	3	(10.7)	11	(8.0)	0	(0.0)	8	(7.0)	3	(6.7)
Total	131		28		137		22		114		45

Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM2B both normal, CI confidence interval, CR complete response, PD progressive disease, PR partial response, RRM1 ribonucleotide reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit, SD stable disease.
^aResponse rate was evaluated for patients with the presence of at least one measurable lesion (n = 159) according to RECIST (Response Evaluation Criteria in Solid Tumors), version 1.0.
^bTotal responses, Fishers exact test P = 0.08.
^cTotal responses, Fishers exact test P = 1.00.
^dTotal responses, Fishers exact test P = 0.46.

ISSN: 1471-2407